DK381889A - Benzamidderivater - Google Patents

Benzamidderivater Download PDF

Info

Publication number
DK381889A
DK381889A DK381889A DK381889A DK381889A DK 381889 A DK381889 A DK 381889A DK 381889 A DK381889 A DK 381889A DK 381889 A DK381889 A DK 381889A DK 381889 A DK381889 A DK 381889A
Authority
DK
Denmark
Prior art keywords
benzamide
Prior art date
Application number
DK381889A
Other languages
English (en)
Other versions
DK381889D0 (da
Inventor
Robert John Naylor
Brenda Naylor
Alain Renaud
Michel Langlois
Original Assignee
Robins Co Inc A H
Delalande Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robins Co Inc A H, Delalande Sa filed Critical Robins Co Inc A H
Publication of DK381889D0 publication Critical patent/DK381889D0/da
Publication of DK381889A publication Critical patent/DK381889A/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK381889A 1988-08-04 1989-08-03 Benzamidderivater DK381889A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP88402041A EP0353371A1 (en) 1988-08-04 1988-08-04 Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides

Publications (2)

Publication Number Publication Date
DK381889D0 DK381889D0 (da) 1989-08-03
DK381889A true DK381889A (da) 1990-02-05

Family

ID=8200414

Family Applications (1)

Application Number Title Priority Date Filing Date
DK381889A DK381889A (da) 1988-08-04 1989-08-03 Benzamidderivater

Country Status (10)

Country Link
US (1) US5017580A (da)
EP (1) EP0353371A1 (da)
JP (1) JPH02256616A (da)
KR (1) KR900002778A (da)
AU (1) AU624402B2 (da)
CA (1) CA1333154C (da)
DK (1) DK381889A (da)
PH (1) PH25427A (da)
PT (1) PT91346B (da)
ZA (1) ZA895797B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0353372B1 (en) * 1988-08-04 1993-02-03 Synthelabo Antischizophrenic-S-N-(1-azabicyclo[2.2.2.]oct-3-yl) benzamides and thiobenzamides
EP0527249B1 (en) * 1991-08-09 1997-12-17 Nec Corporation Carrier recovery apparatus for digital satellite communication system
US5273972A (en) * 1992-03-26 1993-12-28 A. H. Robins Company, Incorporated [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates
US5723103A (en) * 1994-12-09 1998-03-03 Vanderbilt University Substituted benzamides and radioligand analogs and methods of use
AU2001284645A1 (en) * 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
AU2001282873A1 (en) 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001284646A1 (en) 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
PE20021019A1 (es) * 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
CA2455773A1 (en) * 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-aryl 7-aza¬2.2.1|bicycloheptanes for the treatment of disease
EP1453828A2 (en) * 2001-10-16 2004-09-08 AstraZeneca AB Azabicyclic compounds for the treatment of fibromyalgia syndrome
MXPA04004464A (es) * 2001-11-08 2004-08-11 Upjohn Co Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US6852716B2 (en) 2002-02-15 2005-02-08 Pfizer Inc Substituted-aryl compounds for treatment of disease
EP1478646A1 (en) * 2002-02-20 2004-11-24 PHARMACIA & UPJOHN COMPANY Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
US7176198B2 (en) 2002-08-01 2007-02-13 Pfizer Inc. 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
US8435762B2 (en) 2008-10-09 2013-05-07 Howard Hughes Medical Institute Chimeric ligand-gated ion channels and methods of use thereof
CN105687190A (zh) 2008-11-19 2016-06-22 福拉姆医药股份有限公司 用(R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺及其可药用盐治疗认知障碍
KR20180101641A (ko) 2010-05-17 2018-09-12 포럼 파마슈티칼즈 인크. (R)-7-클로로-N-(퀴누클리딘-3-일)벤조[b]티오펜-2-카르복사미드 히드로클로리드 모노히드레이트의 결정질 형태
EP3461481A1 (en) 2012-05-08 2019-04-03 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
CN104418851A (zh) * 2013-09-02 2015-03-18 上海龙翔生物医药开发有限公司 奎宁环衍生物的制备方法及纯化方法
US10370369B2 (en) * 2015-03-31 2019-08-06 Yuki Gosei Kogyo Co. Ltd. Acid addition salt of 3-aminoquinuclidine which does not exhibit deliquescence

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605652A (en) * 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
EP0353372B1 (en) * 1988-08-04 1993-02-03 Synthelabo Antischizophrenic-S-N-(1-azabicyclo[2.2.2.]oct-3-yl) benzamides and thiobenzamides

Also Published As

Publication number Publication date
CA1333154C (en) 1994-11-22
EP0353371A1 (en) 1990-02-07
JPH02256616A (ja) 1990-10-17
DK381889D0 (da) 1989-08-03
ZA895797B (en) 1991-03-27
PT91346B (pt) 1995-07-03
PH25427A (en) 1991-07-01
AU624402B2 (en) 1992-06-11
KR900002778A (ko) 1990-03-23
AU3917489A (en) 1990-02-08
PT91346A (pt) 1990-03-08
US5017580A (en) 1991-05-21

Similar Documents

Publication Publication Date Title
DK218787A (da) Benzamidderivater
ATA901789A (de) Somatostatinpeptid
BR8806093A (pt) Trepano
DK381889D0 (da) Benzamidderivater
ATA172889A (de) Furanderivate
ATA900689A (de) Calcitoninpeptide
DK184489D0 (da) Bicyclodioner
DE68926597D1 (de) Mikrorechner
BR8902098A (pt) Eletrolisador
DK113291A (da) Homogent enzymimmunassay
DK137889D0 (da) Foldeaeske
BR8906898A (pt) Jamela
DK182290A (da) Foldeaeske
DK165575C (da) Loeftesele
DE68926367D1 (de) Hydroxymethylcyclobutylpurine
KR890023207U (ko) 관계수
DD277186A3 (de) Waelzlagerseparator
SE8901229D0 (sv) Minor
BR6800108U (pt) Supercross
BR8803641A (pt) Tele-loto
BR8804416A (pt) Papa-mosca
BR8805477A (pt) Milran transpantaneiro
BR8803070A (pt) Rende-lapis
BR8806232A (pt) Bau-casa
BR8806404A (pt) Multiregua

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment